(Reuters) - Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S. initial public offering on Friday.

The terms of the IPO were not disclosed in the filing.

Strong equity markets, falling interest rates and hopes of a friendlier regulatory environment under the incoming Trump administration have given a push to companies looking to list their shares.

Metsera, founded in 2022 by venture capital firm ARCH Venture and investment firm Population Health Partners, revealed a net loss of $156.26 million in the first nine months of 2024, compared to a loss of $34.18 million in the same period in 2023.

Metsera intends to list its shares on the Nasdaq Global Market under the ticker symbol "MTSR".

BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim Securities and Cantor are the underwriters for the offering.